^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Steroid receptor agonist

    Related drugs:
    2d
    Photobiomodulation, Er:YAG Laser, and Clobetasol in the Treatment of Oral Lichen Planus. (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Medical University of Silesia
    New trial
    5d
    A rare case of littoral cell angioma with paroxysmal nocturnal hemoglobinuria. (PubMed, Medicine (Baltimore))
    This case suggests a potential association between LCA and PNH. Splenectomy provided dual benefits by treating the splenic tumor and improving hemolysis. Given the possible risk of malignant transformation, long-term follow-up is recommended.
    Journal
    |
    CD34 (CD34 molecule) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    |
    ER positive
    |
    prednisone
    6d
    IFM2012-03: Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma (clinicaltrials.gov)
    P2, N=32, Completed, University Hospital, Lille | Unknown status --> Completed | N=80 --> 32
    Trial completion • Enrollment change
    |
    prednisone • carfilzomib • melphalan
    10d
    LASER-LICH1: Laser vs Clobetasol for Lichen Sclerosus (clinicaltrials.gov)
    P3, N=246, Completed, Ruhr University of Bochum | Recruiting --> Completed | Trial completion date: Jul 2025 --> Oct 2025 | Trial primary completion date: Apr 2025 --> Jul 2025
    Trial completion • Trial completion date • Trial primary completion date
    10d
    Signal regulating proteins (SIRPs) participate in sarcoidosis granuloma formation by promoting immune cell aggregation. (PubMed, Respir Res)
    SIRPα is robustly expressed in monocyte/macrophage lineages within human sarcoidosis tissues, and inhibition of SIRPs (ELA026) suppresses sarcoidosis granuloma formation by preventing macrophage adhesion/aggregation.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta) • SIRPA (Signal Regulatory Protein Alpha)
    |
    prednisone
    11d
    Stress and the Nervous System (clinicaltrials.gov)
    P=N/A, N=23, Completed, Brigham and Women's Hospital | Active, not recruiting --> Completed
    Trial completion
    19d
    The Effect of Dexamethasone Administration Route in Pediatric Brachial Plexus Block (clinicaltrials.gov)
    P4, N=90, Recruiting, Poznan University of Medical Sciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    dexamethasone injection
    19d
    HYDROcortisone Versus Placebo for Severe HospItal-acquired Pneumonia in Intensive Care Patients: the HYDRO-SHIP Study (clinicaltrials.gov)
    P=N/A, N=180, Recruiting, Instituto de Assistencia Medica ao Servidor Publico Estadual, Sao Paulo | Trial completion date: Jul 2024 --> Feb 2027 | Trial primary completion date: Apr 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    25d
    Dexamethasone Regimens for BPD Prevention in Preterm Infants (clinicaltrials.gov)
    P3, N=970, Not yet recruiting, The Children's Hospital of Zhejiang University School of Medicine | Initiation date: Jul 2025 --> Feb 2026
    Trial initiation date
    |
    dexamethasone injection
    25d
    Abiraterone/Prednisone + Standard ADT vs Standard ADT for Prostate Cancer Patients With PSMA-Positive Conventional Imaging Negative Pelvic Lymphadenopathy (clinicaltrials.gov)
    P2, N=140, Not yet recruiting, University of Nebraska
    New P2 trial
    |
    abiraterone acetate • prednisone
    26d
    Comparison of Pain Between Supraperiosteal Injection of Dexamethasone Versus Placebo on Postoperative Pain in Teeth With Symptomatic Irreversible Pulpitis (clinicaltrials.gov)
    P=N/A, N=44, Active, not recruiting, College of Physicians and Surgeons Pakistan
    New trial
    |
    dexamethasone injection
    26d
    Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study. (PubMed, Eur Urol Oncol)
    In PROpel, there were no differences in HRQoL or pain scores reported by patients with mCRPC receiving olaparib + abiraterone versus placebo + abiraterone, suggesting that patients can derive a clinical benefit from olaparib + abiraterone while maintaining similar HRQoL in comparison with current standard-of-care treatment. The PROpel trial is registered on ClinicalTrials.gov as NCT03732820.
    P3 data • Journal • PARP Biomarker
    |
    HRD (Homologous Recombination Deficiency)
    |
    Lynparza (olaparib) • abiraterone acetate • prednisone